Tianjin Pharmaceutical Da Ren Tang 达仁堂
3 significant filings since 30 May 2026: 1 on major holder buying, 1 on earnings pre-announcement and 1 on dividend. The latest, on 5 Aug 2026: 达仁堂关于控股股东增持公司S股股份实施结果的公告.
自 30 May 2026 起有 3 份重大公告：major holder buying 1 份、earnings pre-announcement 1 份、dividend 1 份。最新一份（5 Aug 2026）：达仁堂关于控股股东增持公司S股股份实施结果的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 杜向阳 | Unrated | 25 Aug 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。